A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
Not yet recruiting
GlaxoSmithKline
Phase 1/Phase 2
2021-12-31
This clinical trial is designed to determine the maximum tolerated dose of niraparib when
combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer.
Once this is determined, this dose will be tested to identify what impact it has on the tumor
as well as patient reported outcome measures.
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
Not yet recruiting
Joseph Caster, Ph.D., M.D.
Phase 1/Phase 2
2021-12-31
This clinical trial is designed to determine the maximum tolerated dose of niraparib when
combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer.
Once this is determined, this dose will be tested to identify what impact it has on the tumor
as well as patient reported outcome measures.
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
Not yet recruiting
GlaxoSmithKline
Phase 2
2022-09-15
The purpose of the study is to evaluate the efficacy and safety of the combination of
niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile
cancer.
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
Not yet recruiting
H. Lee Moffitt Cancer Center and Research Institute
Phase 2
2022-09-15
The purpose of the study is to evaluate the efficacy and safety of the combination of
niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile
cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
